Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.

Journal of translational medicine - 5 Nov 2011

Hayashi Satoshi, Kumai Takumi, Matsuda Yoshiya, Aoki Naoko, Sato Keisuke, Kimura Shoji, Kitada Masahiro, Tateno Masatoshi, Celis Esteban, Kobayashi Hiroya

Abstract excerpt

BACKGROUND: T-cell based immunotherapy for lung cancer (LC) could be a promising and novel therapeutic approach. Six-transmembrane epithelial antigen of the prostate (STEAP) and the polycomb group protein enhancer of zeste homolog 2 (EZH2) are highly expressed in LC and since the expression of molecules in normal tissue is significantly lower as compared to tumor cells, these proteins are considered as potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Enhancer of Zeste Homolog 2 Protein

Share to Granzymes

Share to Immunotherapy

Share to Oxidoreductases

Share to Polycomb Repressive Complex 2

Source

Open in PubMed Open full text

Identifiers

PMID: 22053850
DOI: 10.1186/1479-5876-9-191
PMCID: PMC3219573

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.PMID 22053850Read ↗

Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine CarcinomasSemantic proximity Read ↗

New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.Semantic proximity Read ↗

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapySemantic proximity Read ↗

Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells.Semantic proximity Read ↗

Evaluation of the Prognostic Value of STEAP1 in Lung Adenocarcinoma and Insights Into Its Potential Molecular Pathways via Bioinformatic AnalysisSemantic proximity Read ↗

Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling PathwaysSemantic proximity Read ↗

Identification of a Cancer Testis Antigen-Associated Six-Gene Signature in Lung Adenocarcinoma for the Prediction of Survival and Response to Immune-Checkpoint InhibitorsSemantic proximity Read ↗

CENPE is a potentially key molecular biomarker and potential therapeutic target for lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.